Adcock shareholders postpone CFR buyout vote; FDA says common ADHD drugs can trigger painful erections;

@FiercePharma: Best-read this morning: GSK scraps doc payments, sales rep quotas in global marketing revamp. More | Follow @FiercePharma

@EricPFierce: FDA, EMA to share "information on inspections of bioequivalence studies" on generics. News | Follow @EricPFierce

@CarlyHFierce: A U.S. competitor to AstraZeneca's Nexium is here. Release | Follow @CarlyHFierce

> Shareholders of South Africa's Adcock Ingram agreed to postpone their vote on a new buyout offer from Chilean drugmaker CFR Pharmaceuticals until next month. Report

> The FDA and the European Medicines Agency (EMA) said they would work together to inspect facilities and data used to support applications for generic-drug approvals. Report

> After a favorable patent ruling, India's Lupin launched its generic version of the ViiV Healthcare HIV treatment Trizivir, with 180 days of marketing exclusivity under the Hatch-Waxman Act. Report

> The FDA's push for abuse-resistant opioid painkillers will disrupt the pain-relief market, Frost & Sullivan analysts said. Report

> ADHD drugs that, like Ritalin, contain the stimulant methylphenidate can caused prolonged, painful erections and even permanent damage to the penis, the FDA said; the median age of patients reporting the condition was 12.5 years. Report

> Alliance Pharma said it had acquired marketing rights in the U.K. and Ireland to Novartis' ($NVS) lip-moisturizing product Lypsyl. Report (sub. req.)

Medical Device News

@FierceMedDev: Medtronic kicks off another renal denervation trial as competitors lag behind. Story | Follow @FierceMedDev

@MarkHFierce: Find out how Dx developer Xagenix attracted a robust Series B despite the tough VC funding environment. Article from FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Artificial cells made en masse offer insight into delivery across membrane. News | Follow @MichaelGFierce

@GalenMoore: Medtronic plans a $6M expansion in Puerto Rico. Takeaway: I get to write about Puerto Rico after I shovel snow. More | Follow @GalenMoore

> Apollo Endosurgery raises $90M to help pay for Allergan's obesity intervention business. Article

> Stryker agrees to settle four metal hip lawsuits as hundreds more loom. Story

> Report: Man peddling a 'Star Trek'-style medical scanner will admit to fraud. Item

Biotech News

@FierceBiotech: After a Phase III flop, Acucela plots a $120M Japanese IPO. More | Follow @FierceBiotech

@JohnCFierce: Gilead races to the FDA with stellar PhIII results for breakthrough hep C combo. Story | Follow @JohnCFierce

@DamianFierce: Transcept: "Retrophin never presented any credible evidence of ability to finance purchase of our stock." Release | Follow @DamianFierce

@EmilyMFierce: Last issue of FierceBiotech Research until 2014: Newsletter. Until then, read us on the web: | Follow @EmilyMFierce

> Onconova tanks as its lead candidate flunks PhIII for pancreatic cancer. News

> Genentech's ex-R&D boss takes the reins at the Gates Foundation. Story

> Merck partners up with GlaxoSmithKline on its prize cancer immunotherapy. Article

Drug Delivery News

> Magnetic sperm-driven micro-robots swim to deliver drugs. More

> Artificial cells made en masse offer insight into delivery across membrane. Article

> Austrian team improves RNAi 'hairpin' structures for more efficient delivery. Story

> 'Walking' DNA motor on nanotube tracks could someday deliver drugs. Piece

> Belgian Cardio3 BioSciences corrals $5.5M for stem cell delivery tech trial. News

> Alnylam begins PhII trial for amyloidosis RNAi treatment. Item

Diagnostics News

> FDA warning: Avoid using test vs. mammography as cancer Dx screening tool. News

> Cynvenio, CollabRx will use data to personalize the cancer Dx process. More

> In tough funding times, Xagenic's detailed Dx work drew plenty of VC. Piece

> Natera finds Hong Kong berth for prenatal screening test. Story

> Navidea wants the FDA to approve a wider use of its injectable cancer imaging agent. Article

> Sundance Diagnostics is linking with Max Planck Institute on a suicide-risk blood test. More

> University of Cambridge finds one test now possible for most blood cancers. Item

And Finally... A woman in China died from a new strain of bird flu, the H10N8 virus. Report

Suggested Articles

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.